stockrowGlass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
Follow GLAS
Alert me
Glass House Brands Inc. (GLAS) EV/Sales
As of 5 November 2026, Glass House Brands Inc. (GLAS) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from 0.0× (December 2024) to 6.9× (June 2026); the current reading is higher than 36% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.3× | 91.09% |
| FY2024 | 2.2× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.7× | 58.24% |
| Mar 2026 | 4.3× | (1.06%) |
| Dec 2025 | 4.3× | 18.95% |
| Sep 2025 | 3.6× | 46.59% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −7.2× |
| AKBA Akebia Therapeutics, Inc. compare | 0.1× |
| OGI Organigram Global Inc. compare | 0.6× |
| GLAS Glass House Brands Inc. | 1.4× |
| DERM Journey Medical Corporation compare | 1.7× |
| ADCT ADC Therapeutics SA compare | 1.9× |
| ANIK Anika Therapeutics Inc. compare | 2.0× |
| LFCR Lifecore Biomedical, Inc. compare | 3.6× |
| SIGA Siga Technologies Inc. compare | 4.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)